These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24114123)

  • 1. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
    Deming DA; Ninan J; Bailey HH; Kolesar JM; Eickhoff J; Reid JM; Ames MM; McGovern RM; Alberti D; Marnocha R; Espinoza-Delgado I; Wright J; Wilding G; Schelman WR
    Invest New Drugs; 2014 Apr; 32(2):323-9. PubMed ID: 24114123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
    Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
    Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
    Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
    Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
    Ogawa Y; Ogura M; Tobinai K; Ando K; Suzuki T; Watanabe T; Ohmachi K; Uchida T; Hanson ME; Tanaka Y; Koh Y; Shimamoto T; Hotta T
    Int J Hematol; 2016 Jan; 103(1):25-33. PubMed ID: 26619834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Portnow J; Frankel P; Koehler S; Twardowski P; Shibata S; Martel C; Morgan R; Cristea M; Chow W; Lim D; Chung V; Reckamp K; Leong L; Synold TW
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):505-14. PubMed ID: 21850464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
    Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
    Fakih MG; Fetterly G; Egorin MJ; Muindi JR; Espinoza-Delgado I; Zwiebel JA; Litwin A; Holleran JL; Wang K; Diasio RB
    Clin Cancer Res; 2010 Jul; 16(14):3786-94. PubMed ID: 20463088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
    Weber DM; Graef T; Hussein M; Sobecks RM; Schiller GJ; Lupinacci L; Hardwick JS; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):319-24. PubMed ID: 23040438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
    Doi T; Hamaguchi T; Shirao K; Chin K; Hatake K; Noguchi K; Otsuki T; Mehta A; Ohtsu A
    Int J Clin Oncol; 2013 Feb; 18(1):87-95. PubMed ID: 22234637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
    Hoang T; Campbell TC; Zhang C; Kim K; Kolesar JM; Oettel KR; Blank JH; Robinson EG; Ahuja HG; Kirschling RJ; Johnson PH; Huie MS; Wims ME; Larson MM; Hernan HR; Traynor AM
    Invest New Drugs; 2014 Feb; 32(1):195-9. PubMed ID: 23728919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
    Friday BB; Anderson SK; Buckner J; Yu C; Giannini C; Geoffroy F; Schwerkoske J; Mazurczak M; Gross H; Pajon E; Jaeckle K; Galanis E
    Neuro Oncol; 2012 Feb; 14(2):215-21. PubMed ID: 22090453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
    J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
    Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U
    Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
    Bommakanti SV; Dudek AZ; Khatri A; Kirstein MN; Gada PD
    Am J Clin Oncol; 2011 Dec; 34(6):597-602. PubMed ID: 21127410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.